The Noom Microdose GLP-1Rx Plus Program offers compounded tirzepatide at a lower dose to support meaningful weight loss with a gentle start. The program includes unlimited access to message your doctor, a dedicated Coach, a personalized curriculum, and tools for tracking protein and managing side effects — plus medication delivered to your door.
To check eligibility and sign up, visit noom.com/med or sign up directly in the Noom app.
This program is not available in Alabama, Louisiana, or Mississippi
FAQs
What are the differences between the Noom GLP-1Rx Plus and Noom Microdose GLP-1Rx Plus Programs?
The Noom Microdose GLP-1Rx Plus Program is designed to stay at a lower dose to help reduce side effects while still supporting meaningful weight loss. The maximum dose in this program is 3 mg compounded tirzepatide.
The Noom GLP-1Rx Plus Program offers a maximum dose of 8.75 mg compounded tirzepatide and is designed to gradually scale dosing over time—offering a dynamic, personalized path for those who may benefit from higher doses of medication.
Both options are backed by Noom’s behavior change tools and clinical care teams—so you get the guidance you need, no matter your path.
How are the Noom GLP-1Rx Plus and Noom Microdose GLP-1Rx Plus Programs different from other weight-loss programs?
Noom Med combines the power of Noom’s proven behavior change weight-loss program with the latest advancements in medical weight-loss technology.
Our goal is not to sell more medications—it’s to drive sustainable weight-loss outcomes.
What are the differences between the Noom Microdose GLP-1Rx and the Noom Microdose GLP-1Rx Plus Programs?
Both programs are designed to support weight loss at lower medication doses — but they differ in the medication offered:
- Noom Microdose GLP-1 Rx uses compounded semaglutide (a GLP-1 receptor agonist) with a maximum dose of 0.6 mg.
- Noom Microdose GLP-1 Rx Plus uses compounded tirzepatide (a dual GLP-1 and GIP receptor agonist) with a maximum dose of 3 mg.
The main distinction is how each medication works: tirzepatide targets two hormonal pathways (GLP-1 and GIP), while semaglutide targets one (GLP-1). Both medications can aid in weight loss, while dual GLP-1 and GIP receptor agonists target appetite control and slower digestion with an additional mechanism.
